Last reviewed · How we verify
GSK Biologicals' Zilbrix™ Hib
GSK Biologicals' Zilbrix™ Hib is a Conjugate vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of invasive disease caused by Haemophilus influenzae type b (Hib) in infants and children. Also known as: DTPw-HBV/Hib vaccine.
Zilbrix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) polysaccharide capsule.
Zilbrix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) polysaccharide capsule. Used for Prevention of invasive disease caused by Haemophilus influenzae type b (Hib) in infants and children.
At a glance
| Generic name | GSK Biologicals' Zilbrix™ Hib |
|---|---|
| Also known as | DTPw-HBV/Hib vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Target | Haemophilus influenzae type b polysaccharide capsule (PRP) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified Hib polyribosyl ribitol phosphate (PRP) polysaccharide conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent immune response. This conjugation allows the vaccine to elicit both IgG antibodies and immunological memory, providing protection against invasive Hib disease including meningitis, bacteremia, and epiglottitis.
Approved indications
- Prevention of invasive disease caused by Haemophilus influenzae type b (Hib) in infants and children
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
Key clinical trials
- Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™ (PHASE3)
- Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers (PHASE2)
- Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Biologicals' Zilbrix™ Hib CI brief — competitive landscape report
- GSK Biologicals' Zilbrix™ Hib updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK Biologicals' Zilbrix™ Hib
What is GSK Biologicals' Zilbrix™ Hib?
How does GSK Biologicals' Zilbrix™ Hib work?
What is GSK Biologicals' Zilbrix™ Hib used for?
Who makes GSK Biologicals' Zilbrix™ Hib?
Is GSK Biologicals' Zilbrix™ Hib also known as anything else?
What drug class is GSK Biologicals' Zilbrix™ Hib in?
What development phase is GSK Biologicals' Zilbrix™ Hib in?
What are the side effects of GSK Biologicals' Zilbrix™ Hib?
What does GSK Biologicals' Zilbrix™ Hib target?
Related
- Drug class: All Conjugate vaccine drugs
- Target: All drugs targeting Haemophilus influenzae type b polysaccharide capsule (PRP)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of invasive disease caused by Haemophilus influenzae type b (Hib) in infants and children
- Also known as: DTPw-HBV/Hib vaccine
- Compare: GSK Biologicals' Zilbrix™ Hib vs similar drugs
- Pricing: GSK Biologicals' Zilbrix™ Hib cost, discount & access